DrugPatentWatch Database Preview
NERLYNX Drug Profile
Which patents cover Nerlynx, and what generic alternatives are available?
Nerlynx is a drug marketed by Puma Biotech and is included in one NDA. There are nine patents protecting this drug.
This drug has one hundred and three patent family members in twenty countries.
The generic ingredient in NERLYNX is neratinib maleate. One supplier is listed for this compound. Additional details are available on the neratinib maleate profile page.
Summary for NERLYNX
| International Patents: | 103 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 74 |
| Clinical Trials: | 2 |
| Patent Applications: | 120 |
| Drug Prices: | Drug price information for NERLYNX |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for NERLYNX |
| DailyMed Link: | NERLYNX at DailyMed |
Generic Entry Opportunity Date for NERLYNX
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for NERLYNX
| (2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide |
| (2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide neratinib |
| (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide |
| (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;HKI-272 |
| (E)-N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide |
| (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylami |
| (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide |
| (E)-N-[4-[3-chloro-4-(2-pyridylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolyl]-4-(dimethylamino)but-2-enamide |
| 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)- |
| 387N096 |
| 4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide |
| 698387-09-6 |
| 698387-09-6, HKI272, HKI 272, HKI-272, |
| 736156-77-7 |
| A25338 |
| AB0008022 |
| ABP000871 |
| AC-25073 |
| AK170454 |
| AKOS005146340 |
| AKOS025149637 |
| AN-546 |
| AOB87125 |
| AS-16279 |
| BC256322 |
| BCP9000984 |
| BCPP000151 |
| BDBM50161957 |
| BIFK0031 |
| BRD-K85606544-001-01-8 |
| C30H29ClN6O3 |
| cc-32 |
| CDP-820 |
| CHEMBL180022 |
| D08950 |
| DB11828 |
| DTXSID70220132 |
| EX-A062 |
| GTPL5686 |
| HKI 272 |
| HKI-272 |
| HY-32721 |
| I06-2375 |
| JJH94R3PWB |
| JSPY-st000262 |
| KB-58129 |
| MolPort-006-069-389 |
| N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide |
| NCGC00241101-01 |
| NCGC00241101-03 |
| Neratinib |
| Neratinib - HKI-272 |
| Neratinib (HKI-272) |
| Neratinib (USAN/INN) |
| Neratinib [USAN:INN] |
| Neratinib HKI 272 |
| Neratinib(HKI-272) |
| Neratinib(HKI-272)/HKI272 |
| PB 272 |
| PB-272 |
| PubChem22399 |
| Q-101402 |
| QCR-104 |
| RL04677 |
| s2150 |
| SB16595 |
| SC-28031 |
| SCHEMBL571762 |
| SCHEMBL571763 |
| SYN1140 |
| Tube708 |
| UNII-JJH94R3PWB |
| WAY-179272 |
| WAY-179272-B |
| X2638 |
| Z-3202 |
| ZINC3916214 |
| ZX-AFC000299 |
US Patents and Regulatory Information for NERLYNX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for NERLYNX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 102369010 | ➤ Sign Up |
| Russian Federation | 2463300 | ➤ Sign Up |
| Japan | 5992325 | ➤ Sign Up |
| New Zealand | 595143 | ➤ Sign Up |
| Japan | 2015127352 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2009052264 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
